1- Editorial policy

Asia Oceania Journal of Nuclear Medicine & Biology (AOJNMB) is a peer reviewed biannual journal and serves as the official publication of Asia Oceania Federation of Nuclear Medicine and Biology (AOFNMB). AOJNMB publishes material of interest to physicians and scientists working in the fields of nuclear medicine & biology. The journal is an open-access free e-Journal which is published by AOFNMB and sponsored by Nuclear Medicine Research Center (NMRC) in Mashhad University of Medical Sciences (MUMS). A limited number of journals in print form are also published. AOJNMB publishes a variety of articles including original laboratory and clinical investigations, meta-analyses, short communications, technical notes, case reports and letters to the editor. Also occasionally, invited reviews and continuing education has been published. In preparing manuscripts, authors should follow the Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publications (http://www.icmje.org/urm_full.pdf). Manuscripts, including figures and tables, must be original and not under consideration for publication elsewhere. Ethics and malpractice statements of the Asia Oceania Journal of Nuclear Medicine & Biology are based on COPE’s Best Practice Guidelines for Journal Editors and pertain to all parties involved in the publishing: the editor, the peer reviewer and the author. If there is an allegation of plagiarism, scientific misconduct or fraud, AOJNMB shall follow the recommendations of the Uniform Requirements and reserves the right to present the allegations to the author’s institution or any other agency.

2- Editorial office

Asia Oceania Journal of Nuclear Medicine & Biology, Nuclear Medicine Research Center, Ghaem Hospital, Ahmadabad Ave, Mashhad, Iran
Post Code: 91766-99199
Tel: +98-511-8400494 (Saturday-Wednesday; 8:00-14:00, Thursday: 8:00-12:00, Local time, GMT+3:30)
Fax: +98-511-8419521
E-mail: aojnmb@mums.ac.ir
All manuscript should be submitted and tracked online. All other enquires should be made by E-mail to aojnmb@mums.ac.ir. Other correspondence may be sent to Prof. Seyed Rasoul Zakavi at the address of editorial office.

3- Legal and ethical issues

- Submission of any manuscript to AOJNMB signifies that it is original and it has not been published anywhere before (except as a congress abstract of no more than 350 words) nor it is under consideration by another journal. By virtue of the submitted manuscript, the corresponding author acknowledges that all the co-authors have seen and approved the final version of the manuscript. The corresponding author should provide all co-authors with information regarding the manuscript, and obtain their approval as well as approval of their institute before submitting any revisions. The editors consider that all submitted materials including text, figures or tables and any other file are original. If it is not the case, the authors must provide both the print and online permission from the copyright
owner. The Asia Oceania Federation of Nuclear Medicine and Biology (AOFNMB) and the sponsor (NMRC and MUMS) will not be held legally responsible should there be any claims for compensation. The authors are responsible for the whole scientific content as well as the accuracy of the bibliographic information.

- At the time of submission of the manuscript, all authors must disclose any type of conflict of interest including but not limited to financial interests that may influence the submitted manuscript. Any company consultancy, product or stock ownership related to the manuscript must be disclosed. Affiliations of authors should include corporate appointments relating to or in connection with the products or companies mentioned in the article. Authors should declare sources of funding for the work undertaken. If there is no conflict of interest for all of the authors, the phrase ‘No potential conflicts of interest were disclosed’ should be written in the acknowledgement.

- All manuscripts reporting the results of experimental investigations involving human subjects should include a statement, confirming that informed written consent was obtained from each subject or the subject’s guardian. The study must also be approved by local ethics committee and the study must comply with 1964 Declaration of Helsinki and its subsequent revisions.

- For animal studies, it must be in compliance with the regulation(s) of local institution and with generally accepted guideline governing such work.

- All prospective clinical trials must be registered. Registration of prospective clinical trials must be done in one of publicly accessible registries and the registration number must be provided at the end of the abstract.

4- As an open-access journal, *AOJNMB* uses licenses that keep the copyright with the author, but the author transfers all commercial exploitation rights to the publisher (AOFNMB). The author(s) can post a copy of the published article on his/her own website or his/her institution’s website with no permission, provided that full citation of the journal and a link to the *AOJNMB* website are included. Also, it can be used in educational materials by author(s) with citation of the AOJNMB. The author(s) may republish the article in a book written or edited by himself/herself without permission, but with full acknowledgment of the first publisher. All authors must complete and sign the copyright transfer form (at the end of this document) and submit it with the manuscript to the editorial office.

5- **Article types**

- Original articles: Manuscripts reporting the results of original researches in preclinical, clinical or technical innovations.

- Meta-analyses: Reporting combined results of individual studies, after a comprehensive search of the available database and using special statistical methods.
• Short communications: A short report from a research work will be published as short communication.

• Case reports: An important and rare presentation of a disease relevant to nuclear medicine or interesting or unusual nuclear medicine images which is either not reported before or infrequently reported.

• Technical notes: A short report on new technical or procedural innovation or modification of established techniques or procedures in nuclear medicine.

• Review articles: Invited reviews and educational materials will be published. The journal prefers systematic reviews. The author(s) of a review article must have at least two published original articles on that subject.

• Letter to the AOJNMB: Letters to the editors on controversial issues which is published in the AOJNMB in the previous issues (no later than 12 months)

• Others: Editorials, History and perspectives, book reviews, upcoming events, meeting reports and news items may be considered for publication.

6- Manuscript submission
All manuscripts should be submitted online using online submission system at http://aojnmb.mums.ac.ir You need to sign up and log into the system for submission of your manuscript. Please follow the on screen instructions during submission. After completion of manuscript submission, you can track the status of the manuscript by logging into the system. For any further enquiry you can send an email to aojnmb@mums.ac.ir

7- Manuscript preparation: The manuscript should have the following sections: Title, Abstract, Main document, Acknowledgement, References, Figures and Tables.

7-1: Title page should include in following order: Title (please keep it short and informative), Full first name and surname (and middle name initials) of all authors, Affiliation(s) and e-mail address(es) of all authors, Corresponding author’s Full name, postal address, e-mail address, Telephone and Fax number(s). We encourage authors to include their ORCID number, if they have any. A short running title of less than 40 characters must be added at the end of Title page.

7-2: Abstract: The abstract page begins with Title of the article with no author(s) name. The abstract should contain a Maximum of 350 words divided in 4 sections preceded by headings: Objective, Methods, Results and conclusion. For review articles and case reports an unstructured abstract with a maximum of 200 words is required. Three to five keywords are necessary for all abstracts. Word count should be written at the bottom of abstract page.
7-3: **Main document**:

7-3-1: The abstract must be the first page of Main document. For original articles, the following sections should be included: Introduction, Methods, Results, Discussion and Conclusion. For reporting Clinical Trials, please follow reporting requirements published by CONSORT: [http://www.consort-statement.org/consort-statement](http://www.consort-statement.org/consort-statement) (There is no maximum word limit, but it is preferable to keep Maximum word count at 6000 and Maximum references at 40).

7-3-2: For short communications and technical notes, the following sections should be included: Introduction, Methods, Results, Discussion and Conclusion. (Maximum word count 3000 and Maximum references 20)

7-3-3: For case reports, three sections of Introduction, Case report and Discussion are required. (Maximum word count 3000 and Maximum references 20)

7-3-4: For Meta-analyses, Introduction, Methods, Results, Discussion and Conclusion should be included. Please use PRISMA statement for reporting your work: [http://www.prisma-statement.org/statement.htm](http://www.prisma-statement.org/statement.htm) (There is no maximum word limit, but it is preferable to keep Maximum word count at 6000 and Maximum references at 40)

7-3-5: For review articles; (There is no maximum word limit, but it is preferable to keep Maximum word count at 6000 and Maximum references at 40)

7-4: **Formatting**:

- Use MS Word 97 or later versions.
- Use plain normal fonts (12 Times New Roman) with double space formatting throughout the document including abstract, manuscript and references.
- Leave 3 cm margin on each side of the page.
- Number pages consecutively, beginning from the Abstract and put it in right upper corner of the page.
- Do not use field function, do not use the space bar, instead use tab stops.
- Cite every reference in the text in parenthesis using Vancouver style (Parenthesis) in the order they appear in the text. Using Endnote for citation is encouraged.
- Paragraphs should begin with an indentation (One tab of at least five-spaces length).
- Use the equation editor or MathType for inserting equations.
- The abbreviations should be used according to Système Internationale (SI) nomenclature and units and they should be explained the first time they are used in the manuscript. All units of radioactivity should be based on the SI system *i.e.*, Bq, Gy, Sv, *etc*. Chemical formulae should be written according to the recommendations of the American Chemical Society.

7-5: **Acknowledgement**: Acknowledgements, sponsorship or grants should be written after the main text and before the references.

7-6: **References**:

The references should be listed consecutively in order of citation in the manuscript. All references must be cited either in text, table or figures. Unpublished data and personal
communications cannot be cited. The AOJNMB uses Vancouver style for references. For citation of journals, all authors should be listed if the number of authors were 6 or less. If there is more than six authors in an article, please list the first 6 authors followed by et al. A paper published online but not in print can be cited using the Digital Object Identifier (DOI). A web document can be cited using the URL address mentioning date of access. Using ENDNOTE or similar software and selecting the Vancouver style (Parenthesis) in Bibliographic Output Style will facilitate correct reference citation.

Here are samples of citation styles:

a) Journal article (With 6 or less authors)

b) Journal article (With more than 6 authors)

c) Book

d) Book chapter

e) Epub; Article by DOI:

f) Online document:

7-7: Figure legends: Figure legends should be written after references, each in a separate sheet preceding with figure number (Figure 1). The figure legends will be published below the figure. The legend should not be included in the figure file. All figures must be cited in the manuscript and numbered consecutively using Arabic numerals.
7-8: Tables: Tables should not be sent as figures or as separate file, they should be inserted at the end of the manuscript, each in a separate sheet. Tables are expected to be self explanatory, should supplement and not duplicate the text and numbered consecutively in order of appearance in the text and using Arabic numerals. Put horizontal line at the top of the table, below column headings and at the bottom of it. Do not use vertical line in the tables.

8: Figures and artworks: Figures and artwork should be submitted as separate files in JPG or TIFF format. Figures should be utilized only if they augment understandability of the text. Drawings and graphs should be professionally prepared in deep black and white with no shading. Professionally designed computer generated graphs with a minimum of 300 DPI laser printer output is preferable. Color photographs are welcomed. Vector graphics containing fonts must have the fonts embedded in the files. For lettering the figures, use 8-12 point (only one size) Helvetica fonts. Name each figure with the word “Fig” followed by figure number without punctuation: “Fig1”. If you include a figure from previous publication, you must provide permission from the copyright owner(s) for both the print and online format.

9: Supplementary materials: Video clips, sound records, excel or SPSS files and other supplementary materials could be sent for electronic linking to the manuscript in the website. MPEG-1 format (.mpg) should be used for video clips. Supplementary documents are encouraged to be sent as .PDF files if possible. Please name each supplementary file beginning with the name of first author (eg. Bom-video.mpg, Sadeghi-data.xls, etc). In text files you should enter the full name of the article and the authors as a header.

10: Cover letter: All manuscripts should be accompanied by a cover letter. In the cover letter signed by corresponding author on behalf of all authors, it must be mentioned that the article is not submitted to any other journal. A sample of cover letter could be found at the end of this document.

11: Peer review process: All manuscripts will be peer reviewed prior to publication. Authors are encouraged to suggest names of three expert reviewers, but selection remains a prerogative of the Editor. The whole review process depends on receiving referees’ comments and revising the manuscripts based on these comments to the author and may take few months. AOJNMB will try to make the time between submission and final decision as short as possible. On receipt of the revised article from the author, and after final approving by the referees, the letter of acceptance is issued to the author.

12: Acceptance/Rejection: You will be notified regarding acceptance or rejection of the article by e-mail. Upon acceptance and after editorial amendments, galley proof will be sent to the corresponding author for final correction. No major change in content or title is accepted at this stage without editor’s approval. Any addition or removal of an author from the list of authors
must be accompanied with a written and signed agreement of the author(s) to be added or deleted.

Asia Oceania Journal of Nuclear Medicine & Biology
Authorship Responsibility, Financial Disclosure, and Copyright Transfer

Manuscript title:”..........................................................”
Corresponding author: .................
Mailing address, Tel and Fax numbers:
Each author must read and sign the following statements. Completed and signed form should be sent by Fax to editorial office. Alternatively you can scan the signed form and send by e-mail to aojnmb@mums.ac.ir
We undersigned, the co-authors of the manuscript entitled: ” .............................................. 
....................” submitted to Asia Oceania Journal of Nuclear Medicine & Biology attest that : 1) the work described has not been previously published in this or similar form(electronically or in print), nor is it under consideration for publication elsewhere; 2) all co-authors have approved submission for publication in the AOJNMB; 3) approval for publication in AOJNMB has been obtained from the institution where the work has been carried out; 4) the clinical or research work covered in this article, was confirmed by ethics committee of affiliated institution(s) and comply with 1964 Declaration of Helsinki and its subsequent revisions 5) we have herein disclosed any and all financial or other relationships that could be construed as a conflict of interest and that all sources of financial support for this study have been disclosed and are indicated in the acknowledgments.; 6) each of the authors of the article has contributed significantly to the design, analysis and/or interpretation, writing or critiquing drafts of the manuscript and has approved the final manuscript before publication; 7) upon acceptance of the manuscript for publication, all commercial exploitation rights for the above publication will be transferred to the AOJNMB.
The publisher will not be held legally responsible should there be any claims for compensation or copyright infringement.

Corresponding Author’s Signature       Date
Author’s (printed name) Signature       Date
Author’s (printed name) Signature       Date
Author’s (printed name) Signature       Date
Sample cover letter

Dear Editor;

We are pleased to submit the manuscript titled “....................” for considering to publish in the “Asia Oceania Journal of Nuclear Medicine & Biology”. The present manuscript prepared according to the instruction of the journal.

On behalf of all authors I hereby confirm that neither the manuscript nor any part of it, except for abstracts of less than 350 words, has been published or is being considered for publication elsewhere. By signing this letter I acknowledge that all authors participated sufficiently in the work to take public responsibility for its content.

This manuscript has not been published or submitted elsewhere and will not be submitted for publication elsewhere until the editorial board has decided whether to publish the article.

Corresponding author’s signature.